Strassburg C P, Neubauer V, Poliwoda H, Benter T
Department of Hematology and Oncology, Hannover School of Medicine, Germany.
Neoplasma. 1992;39(6):343-7.
RNA transcriptional levels of the proto-oncogenes c-sis, c-fos, c-myb and c-myc were measured in peripheral blood leukemic blast cells of 16 patients with acute myeloid leukemia (AML) of different FAB subtypes, 8 being at diagnosis and 8 upon relapse. The studied proto-oncogenes were found to be regulated but varied considerably within morphologically identical subtypes. This is consistent with the clinically observable diverse behavior of seemingly identical AMLs as to the course and outcome of the individual disease. Overexpression of c-sis and c-myc was found more often in AML upon relapse than at diagnosis and in two cases overexpression not found at diagnosis was present at relapse. This implies alterations of biological behavior in the course of antileukemic drug therapy. A decline of c-myb expression was observed in one patient studied throughout therapy which was found to be associated with a complete but transient hematological remission after chemotherapy.
在16例不同FAB亚型的急性髓系白血病（AML）患者的外周血白血病原始细胞中，检测了原癌基因c-sis、c-fos、c-myb和c-myc的RNA转录水平，其中8例为初诊患者，8例为复发患者。研究发现，所研究的原癌基因受到调控，但在形态学相同的亚型中差异很大。这与临床上观察到的看似相同的AML在个体疾病的病程和转归方面表现出的不同行为是一致的。与初诊时相比，c-sis和c-myc的过表达在复发的AML中更为常见，并且在两例患者中，初诊时未发现过表达，而在复发时出现了过表达。这意味着在抗白血病药物治疗过程中生物学行为发生了改变。在整个治疗过程中对一名患者进行研究时观察到c-myb表达下降，发现这与化疗后完全但短暂的血液学缓解有关。
